US Autoimmune Hemolytic Anemia Therapeutics Market Projected to Grow at 5.6% CAGR from 2024 to 2030, Supported by Increasing Awareness and Diagnosis Rates | DataM Intelligence

Leander, Texas and TOKYO, Japan - The United States Autoimmune Hemolytic Anemia Therapeutics Market is valued at approximately USD 250 million in 2023 and is projected to reach about USD 366 million by 2030, growing at a CAGR of around 5.6% during the forecast period from 2024 to 2030.

This growth is driven by the increasing incidence of autoimmune hemolytic anemia (AIHA) in the U.S., advancements in therapeutic options including biologics and targeted therapies, and supportive healthcare infrastructure along with favorable reimbursement policies. The widespread adoption of novel treatments such as kinase inhibitors and monoclonal antibodies, coupled with accelerated drug approvals through FDA orphan drug and fast track programs, further propel market expansion.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/autoimmune-hemolytic-anemia-therapeutics-market?ram

United States: Key Industry Developments

✅ October 2025: Johnson & Johnson initiated a Phase III trial for its anti-CD20 monoclonal antibody therapy targeting refractory AIHA in North America.

✅ August 2025: Novartis reported promising early results from a Syk inhibitor therapy showing improved hemoglobin levels and reduced hemolysis in AIHA clinical cohorts.

✅ April 2025: The FDA granted priority review status to AstraZeneca's investigational therapy, Fasinumab, in the context of AIHA treatment.

Key Mergers and Acquisitions (2025):

✅ Recordati - acquired global rights for Enjaymo, a treatment for cold agglutinin disease (a related autoimmune hemolytic anemia condition), from Sanofi in October 2024 for $825 million, strengthening its position in rare disease therapeutics and expanding its AIHA-related portfolio.

✅ Bristol Myers Squibb - obtained Asian market rights to obexelimab from Zenas BioPharma in September 2023 with a $50 million investment to augment its therapeutic offerings for autoimmune hemolytic anemia.

✅ Major pharmaceutical players such as Sanofi, Novartis, Johnson & Johnson, Roche, and Pfizer continue to pursue strategic acquisitions and partnerships with biotech firms and research institutions to acquire promising AIHA therapeutic candidates, expand pipelines, and accelerate innovative drug development in 2025.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=autoimmune-hemolytic-anemia-therapeutics-market?ram (Purchase 2 or more Reports and get 50% Discount)

Growth Drivers:

-Increasing prevalence and diagnosis of autoimmune hemolytic anemia worldwide, particularly in aging populations.

-Advancements and approvals of novel therapeutic drugs including biologics, monoclonal antibodies, and immunosuppressants.

-Rising R&D activities and regulatory support accelerating new AIHA drug development and market entry.

-Growing patient awareness and adoption of personalized medicine approaches for targeted and safer treatments.

-Expansion of healthcare infrastructure and e-commerce platforms improving access to AIHA therapeutics globally.

-Increasing investment and partnerships in biopharmaceuticals and biotech sectors focused on autoimmune disorders.

Market Segmentation Analysis:

-By Drug Class

Corticosteroids: Largest segment with approximately 38% market share in 2025, due to their established role as first-line therapy offering rapid hemolysis reduction and cost-effectiveness.

Monoclonal Antibodies: Fastest-growing segment gaining momentum as second-line and, in some cases, first-line treatment, with agents like rituximab delivering targeted B-cell depletion and fewer side effects.

Others: Includes immunosuppressants like IVIG, complement inhibitors, and emerging biologics.

-By Route of Administration

Oral: Predominantly corticosteroids and other small molecule drugs.

Injectable: Mainly monoclonal antibodies and biologics requiring infusion or injection.

-By Therapy Type

First Line Therapy: Corticosteroids remain the primary choice.

Second Line Therapy: Monoclonal antibodies and immunosuppressive drugs.

Third Line Therapy: Emerging treatments including experimental gene and cellular therapies, stem cell transplants.

-By Distribution Channel

Hospital Pharmacy: Largest share, driven by inpatient treatment and infusion administration facilities.

Retail Pharmacy: For outpatient prescriptions and chronic management.

E-Pharmacy: Rapidly growing due to increasing digital health adoption and patient convenience.

-By Disease Type

Cold Antibody Hemolytic Anemia (Cold AIHA): Represents a smaller but significant patient subset, requiring specific treatments like complement inhibitors.

Warm Antibody Hemolytic Anemia (Warm AIHA): Majority of AIHA cases, typically managed with corticosteroids and monoclonal antibodies.

-By Treatment

Medication: Majority of treatment modalities, including steroids, immunotherapy, and biologics.

Surgery: Rare, used in severe refractory cases, such as splenectomy.

Regional Insights:

North America: This region dominates the AIHA therapeutics market with approximately 39.3% market share, driven by advanced healthcare infrastructure, high awareness and prevalence of autoimmune diseases, strong reimbursement frameworks, and extensive use of innovative therapies such as biologics and personalized medicines. The United States leads due to rapid approval processes, high research and development activity, and government policies supporting rare disease treatments, making it the largest revenue contributor at around USD 490-620 million range based on various estimates.

Asia-Pacific: Expected to be the fastest-growing region propelled by increasing disease awareness, improving healthcare infrastructure, expanding diagnostic capabilities, and rising healthcare spending. Key markets include China, India, and Japan, where rising autoimmune disease detection rates, government initiatives to expand therapy access, and growing adoption of targeted immunosuppressive therapies contribute to market growth. The region is also benefiting from collaborations between local and international pharma companies and medical tourism, supporting robust CAGR growth.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/autoimmune-hemolytic-anemia-therapeutics-market?ram

Key Players:

Amneal Pharmaceuticals, Inc. | Incyte Corp. | Kezar Life Sciences, Inc. | Rigel Pharmaceuticals, Inc. | F. Hoffmann-La Roche Ltd. | Sanofi | Pfizer, Inc. | Baxter International, Inc. | Mylan NV | Teva Pharmaceutical Industries Ltd.

Key Highlights (Top 5 Key Players) for Autoimmune Hemolytic Anemia Therapeutics Market:

-Amneal Pharmaceuticals, Inc. reported quarter revenues of $731 million in Q4 2024, with an 18% increase YoY driven by new product launches, biosimilars, and specialty products.

-Sanofi is recognized as a key player in the autoimmune hemolytic anemia -therapeutics market, contributing significantly to overall market growth with ongoing R&D and product expansion.

-F. Hoffmann-La Roche Ltd. is a major competitor focusing on innovative monoclonal antibodies and therapeutic solutions in the autoimmune hemolytic anemia space.

-Pfizer, Inc. maintains strong market presence with a diversified portfolio of therapies addressing autoimmune hemolytic anemia alongside other immunological diseases.

-Incyte Corp. is prominently involved in product development and strategic collaborations targeting autoimmune blood diseases, contributing to its rising market share.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?ram

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.